Sara Donati

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Disease Progression

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Guarneri Valentina; Donati Sara; Nicolini Massimiliano; Giovannelli Simona; D'Amico Roberto; Conte Pier Franco
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.
Conte P F; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato A G; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Guarneri V; Bengala C; Orlandini C; Gennari A; Donati S; Campani D; Collecchi P; Maur M; Conte P F
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Sara Donati (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2005: Guarneri Valentina; Donati Sara; Nicolini Massimiliano; Giovannelli Simona; D'Amico Roberto; Conte Pier Franco
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.
The oncologist 2005;10(10):842-8.
2005: Conte P F; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato A G; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
British journal of cancer 2005;93(4):406-11.
2004: Guarneri V; Bengala C; Orlandini C; Gennari A; Donati S; Campani D; Collecchi P; Maur M; Conte P F
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Bone marrow transplantation 2004;34(5):413-7.
2004: Gennari A; Bruzzi P; Orlandini C; Salvadori B; Donati S; Landucci E; Guarneri V; Rondini M; Ricci S; Conte P
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
British journal of cancer 2004;90(5):962-7.
2004: Cappuzzo F; Mazzoni F; Gennari A; Donati S; Salvadori B; Orlandini C; Cetto G L; Molino A; Galligioni E; Mansutti M; Tumolo S; Lucentini A; Valduga F; Bartolini S; Crinò L; Conte P F
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
British journal of cancer 2004;90(1):31-5.
2003: Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte P F
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bone marrow transplantation 2003;31(4):275-80.
2002: Fogli S; Danesi R; Gennari A; Donati S; Conte P F; Del Tacca M
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(6):919-27.
2001: Venturini M; Michelotti A; Papaldo P; Del Mastro L; Bergaglio M; Lionetto R; Lunardi G; Sguotti C; Frevola L; Donati S; Rosso R; Cognetti F
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(8):1097-106.
2001: Conte P F; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Breast cancer research and treatment 2001;68(2):171-9.
2001: Conte P; Gennari A; Landucci E; Guarneri V; Donati S; Salvadori B; Bengala C; Orlandini C
New combinations with epirubicin in advanced breast cancer.
Oncology (Williston Park, N.Y.) 2001;15(5 Suppl 7):24-7.
2001: Conte P; Gennari A; Guarneri V; Landucci E; Donati S; Salvadori B; Bengala C; Orlandini C; Baldini E
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Oncology (Williston Park, N.Y.) 2001;15(5 Suppl 7):21-3.
2001: Conte P; Salvadori B; Donati S; Landucci E; Gennari A
Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer.
Seminars in oncology 2001;28(2 Suppl 7):15-7.
2001: Conte P; Salvadori B; Donati S; Gennari A; Cetto G L; Molino A; Crino L; Mazzoni F; Galligioni E; Mansutti M
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Oncology (Williston Park, N.Y.) 2001;15(2 Suppl 3):41-3.
2001: Bengala C; Pazzagli I; Innocenti F; Donati S; Favre C; Menconi M C; Greco F; Danesi R; Orlandini C; Guarneri V; Del Tacca M; Conte P F
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):69-74.
2000: Gennari A; Donati S; Salvadori B; Giorgetti A; Salvadori P A; Sorace O; Puccini G; Pisani P; Poli M; Dani D; Landucci E; Mariani G; Conte P F
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Clinical breast cancer 2000;1(2):156-61; discussion 162-3.
2000: Gennari A; Donati S; Danesi R; Fogli S; Orlandini C; Del Tacca M; Conte P F
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Seminars in oncology 2000;27(1 Suppl 2):14-9.
1999: Gennari A; Salvadori B; Donati S; Bengala C; Orlandini C; Danesi R; Del Tacca M; Bruzzi P; Conte P F
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3596-602.
1999: Del Mastro L; Gennari A; Donati S
Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 5():S91-4.
1997: Michelotti A; Salvadori B; Donati S; Tognoni A; Tibaldi C; Conte P F
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients.
Tumori 1997;83(5):826-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Sara Donati

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Sara Donati (preview)

All Publications